We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
News

IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA

IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
News

IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

IPSOGEN has announced the signing of an agreement with Laboratory Corporation of America® Holdings under which LabCorp will offer a JAK2 molecular diagnostic assay in the USA.

According to the terms of the agreement, IPSOGEN grants LabCorp non-exclusive rights, for the US territory, to offer an assay for the molecular classification and the diagnosis of a group of leukemias caused by JAK2 gene variations.

Additional terms were not disclosed. The test is based on mutations in the JAK2 gene, to which IPSOGEN has worldwide exclusive intellectual property rights. A high proportion of patients with myeloproliferative disorders (MPD; polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis) carry a dominant gain-offunction V617F mutation in the JH2 kinase-like domain of JAK2.

This pioneering work published in a 2005 issue of Nature by the INSERM team of Dr. Vainchenker (Institut Gustave Roussy, Paris) provides a breakthrough progress for the molecular classification and the diagnosis of myeloproliferative disorders. The license allows LabCorp to provide the JAK2 mutation assay through its various CLIA-registered laboratories throughout the USA.

Advertisement